Acetylcholine receptor-induced experimental myasthenia gravis: What have we learned from animal models after three decades?

Archivum Immunologiae et Therapiae Experimentalis

Volumn 60, Issue 1, 2012, Pages 19-30

  Baggi, Fulvio ^a   Antozzi, Carlo ^a   Toscani, Chiara ^a   Cordiglieri, Chiara ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Autoimmunity; Experimental model; Myasthenia gravis; Neuroimmunology

Indexed keywords

AZATHIOPRINE; BORTEZOMIB; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C6; COMPLEMENT COMPONENT C9; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; MITOMYCIN C; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIXANTRONE; ROQUINIMEX;

ACTIVE TRANSPORT; ADOPTIVE TRANSFER; AUTOIMMUNE DISEASE; DENDRITIC CELL; DISEASE PREDISPOSITION; DRUG EFFICACY; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NONHUMAN; PASSIVE TRANSPORT; PATHOGENESIS; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; AUTOANTIBODIES; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; NEUROMUSCULAR JUNCTION; RECEPTORS, CHOLINERGIC;

EID: 84858800607     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-011-0158-6     Document Type: Review

References (110)

1. Abramsky O, Tarrab-Hazdai R, Aharonov A et al (1976) Immunosuppression of experimental autoimmune myasthenia gravis by hydrocortisone and azathioprine. J Immunol 117:225-228
2. Antozzi C, Gemma M, Regi B et al (1991) A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol 238:103-107
3. Arce S, Cassese G, Hauser A et al (2002) The role of long-lived plasma cells in autoimmunity. Immunobiology 206:558-562 (Pubitemid 36192915)
4. Aricha R, Feferman T, Fuchs S et al (2008) Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J Immunol 180:2132-2139
5. Aricha R, Feferman T, Scott HS et al (2011) The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells. J Autoimmun 36:16-24
6. Baggi F, Andreetta F, Caspani E et al (1999) Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J Clin Invest 104:1287-1295 (Pubitemid 29536299)
7. Baggi F, Annoni A, Ubiali F et al (2004) Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J Immunol 172:2697-2703 (Pubitemid 38182422)
8. Balandina A, Lecart S, Dartevelle P et al (2005) Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105:735-741 (Pubitemid 40070760)
9. Balasa B, Deng C, Lee J et al (1997) Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J Exp Med 186:385-391 (Pubitemid 27332896)
10. Balasa B, Deng C, Lee J et al (1998) The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J Immunol 161:2856-2862 (Pubitemid 28425707)
11. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252 (Pubitemid 28155090)
12. Barchan D, Souroujon MC, Im SH et al (1999) Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit. Proc Natl Acad Sci USA 96:8086-8091 (Pubitemid 29328412)
13. Bellone M, Ostlie N, Lei SJ et al (1991) The I-Abm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor. J Immunol 147:1484-1491
14. Berman PW, Patrick J (1980a) Experimental myasthenia gravis. A murine system. J Exp Med 151:204-223 (Pubitemid 10172208)
15. Berman PW, Patrick J (1980b) Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis. J Exp Med 152:507-520 (Pubitemid 10059485)
16. Biesecker G, Gomez CM (1989) Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 142:2654-2659 (Pubitemid 19114877)
17. Biesecker G, Koffler D (1988) Resistance to experimental autoimmune myasthenia gravis in genetically inbred rats. Association with decreased amounts of in situ acetylcholine receptorantibody complexes. J Immunol 140:3406-3410
18. Chamberlain-Banoub J, Neal JW, Mizuno M et al (2006) Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin Exp Immunol 146:278-286 (Pubitemid 44581343)
19. Christadoss P (1988) C5 gene influences the development of murine myasthenia gravis. J Immunol 140:2589-2592
20. Christadoss P, Poussin M, Deng C (2000) Animal models of myasthenia gravis. Clin Immunol 94:75-87 (Pubitemid 30067872)
21. Conti-Fine BM, Milani M, Kaminski HJ (2006) Myasthenia gravis: past, present, and future. J Clin Invest 116:2843-2854 (Pubitemid 44684466)
22. Dau PC (1981) Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients. Ann NY Acad Sci 377:700-708
23. Deng C, Goluszko E, Tuzun E et al (2002) Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol 169:1077-1083 (Pubitemid 34753468)
24. Drachman DB (2003) Autonomic "myasthenia": the case for an autoimmune pathogenesis. J Clin Invest 111:797-799
25. Drachman DB, Angus CW, Adams RN et al (1978) Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 298:1116-1122 (Pubitemid 8340619)
26. Duan RS, Adikari SB, Huang YM et al (2004) Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells. Neurobiol Dis 16:461-467 (Pubitemid 38757326)
27. Eldefrawi ME (1978) Experimental autoimmune myasthenia gravis: the rabbit as an animal model. Fed Proc 37:2823-2827
28. Engel AG, Fumagalli G (1982) Mechanisms of acetylcholine receptor loss from the neuromuscular junction. Ciba Found Symp (90):197-224
29. Engel AG, Lambert EH, Howard FM (1977) Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin Proc 52:267-280 (Pubitemid 8113467)
30. Fattorossi A, Battaglia A, Buzzonetti A et al (2005) Circulating and thymic CD4 CD25 T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116:134-141 (Pubitemid 41208360)
31. Goluszko E, Deng C, Poussin MA et al (2002) Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis. J Neuroimmunol 122:85-93 (Pubitemid 34075493)
32. Gomez CM, Richman DP (1983) Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci USA 80:4089-4093 (Pubitemid 13072778)
33. Gomez AM, Van Den Broeck J, Vrolix K et al (2010) Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 43:353-370
34. Gomez AM, Vrolix K, Martinez-Martinez P et al (2011) Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 186:2503-2513
35. Hill M, Moss P, Wordsworth P et al (1999) T cell responses to D-penicillamine in drug-induced myasthenia gravis: recognition of modified DR1:peptide complexes. J Neuroimmunol 97:146-153 (Pubitemid 29301424)
36. Hoch W, McConville J, Helms S et al (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7:365-368 (Pubitemid 32224355)
37. Hoedemaekers AC, Verschuuren JJ, Spaans F et al (1997a) Age-related susceptibility to experimental autoimmune myasthenia gravis: immunological and electrophysiological aspects. Muscle Nerve 20:1091-1101 (Pubitemid 27352090)
38. Hoedemaekers AC, van Breda Vriesman PJ, De Baets MH (1997b) Myasthenia gravis as a prototype autoimmune receptor disease. Immunol Res 16:341-354 (Pubitemid 28026419)
39. Im SH, Barchan D, Fuchs S et al (1999) Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. J Clin Invest 104:1723-1730 (Pubitemid 30053189)
40. Janssen SP, Phernambucq M, Martinez-Martinez P et al (2008) Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J Neuroimmunol 201-202:111-120
41. Kaminski HJ, Kusner LL, Richmonds C et al (2006) Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp Neurol 202:287-293 (Pubitemid 44692673)
42. Karachunski PI, Ostlie NS, Okita DK et al (1999) Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor. J Neuroimmunol 95:73-84 (Pubitemid 29173024)
43. Karachunski PI, Ostlie NS, Monfardini C et al (2000) Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J Immunol 164:5236-5244 (Pubitemid 30305201)
44. Karussis DM, Lehmann D, Brenner T et al (1994) Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J Neuroimmunol 55:187-193
45. Kong QF, Sun B, Bai SS et al (2009a) Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-beta. J Neuroimmunol 207:83-91
46. Kong QF, Sun B, Wang GY et al (2009b) BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Eur J Immunol 39:800-809
47. Lennon VA, Lindstrom JM, Seybold ME (1975) Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J Exp Med 141:1365-1375
48. Lennon VA, Seybold ME, Lindstrom JM et al (1978) Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis. J Exp Med 147:973-983 (Pubitemid 8318067)
49. Lennon VA, Lambert EH, Leiby KR et al (1991) Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol 146:2245-2248
50. Lin F, Kaminski HJ, Conti-Fine BM et al (2002) Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J Clin Invest 110:1269-1274 (Pubitemid 35285753)
51. Lindstrom J (1980) Experimental autoimmune myasthenia gravis. J Neurol Neurosurg Psychiatry 43:568-576
52. Lindstrom J (2008) 'Seronegative' myasthenia gravis is no longer seronegative. Brain 131(Pt 7):1684-1685
53. Lindstrom JM, Seybold ME, Lennon VA et al (1976) Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26:1054-1059
54. Link H, Xiao BG (2001) Rat models as tool to develop new immunotherapies. Immunol Rev 184:117-128 (Pubitemid 34123769)
55. Liu R, Hao J, Dayao CS et al (2009) T-bet deficiency decreases susceptibility to experimental myasthenia gravis. Exp Neurol 220:366-373
56. Liu R, Zhou Q, La Cava A et al (2010) Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol 40:1577-1589
57. Losen M, Stassen MH, Martinez-Martinez P et al (2005) Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain 128(Pt 10):2327-2337 (Pubitemid 41407973)
58. Luo J, Taylor P, Losen M et al (2009) Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J Neurosci 29:13898-13908
59. Mantegazza R, Bonanno S, Camera G et al (2011) Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat 7:151-160
60. Mareska M, Gutmann L (2004) Lambert-Eaton myasthenic syndrome. Semin Neurol 24:149-153 (Pubitemid 38971841)
61. Martinez-Martinez P, Losen M, Duimel H et al (2007) Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. Am J Pathol 170:644-657 (Pubitemid 47339401)
62. Martino G, DuPont BL, Wollmann RL et al (1993) The human-severe combined immunodeficiency myasthenic mouse model: a new approach for the study of myasthenia gravis. Ann Neurol 34:48-56 (Pubitemid 23188726)
63. Matsui N, Nakane S, Saito F et al (2010) Undiminished regulatory T cells in the thymus of patients with myasthenia gravis. Neurology 74:816-820
64. Meinl E, Klinkert WE, Wekerle H (1991) The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am J Pathol 139:995-1008
65. Melms A, Luther C, Stoeckle C et al (2006) Thymus and myasthenia gravis: antigen processing in the human thymus and the consequences for the generation of autoreactive T cells. Acta Neurol Scand Suppl 183:12-13
66. Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475-490
67. Milani M, Ostlie N, Wu H et al (2006) CD4+ T and B cells cooperate in the immunoregulation of experimental autoimmune myasthenia gravis. J Neuroimmunol 179:152-162 (Pubitemid 44441600)
68. Moiola L, Galbiati F, Martino G et al (1998) IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur J Immunol 28:2487-2497 (Pubitemid 28362723)
69. Morgan BP, Chamberlain-Banoub J, Neal JW et al (2006) The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol 146:294-302 (Pubitemid 44581345)
70. Mu L, Sun B, Kong Q et al (2009) Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 128(1 suppl):e826-e836
71. Nessi V, Nava S, Ruocco C et al (2010) Naturally occurring CD4+ CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis. J Immunol 185:5656-5667
72. Newsom-Davis J, Willcox N, Calder L (1981) Thymus cells in myasthenia gravis selectively enhance production of antiacetylcholine-receptor antibody by autologous blood lymphocytes. N Engl J Med 305:1313-1318 (Pubitemid 12234737)
73. Ostlie N, Milani M, Wang W et al (2003) Absence of IL-4 facilitates the development of chronic autoimmune myasthenia gravis in C57BL/6 mice. J Immunol 170:604-612 (Pubitemid 36026189)
74. Patrick J, Lindstrom J (1973) Autoimmune response to acetylcholine receptor. Science 180:871-872
75. Penn AS, Low BW, Jaffe IA et al (1998) Drug-induced autoimmune myasthenia gravis. Ann NY Acad Sci 841:433-449 (Pubitemid 28362881)
76. Pestronk A, Drachman DB, Teoh R et al (1983) Combined short-term immunotherapy for experimental autoimmune myasthenia gravis. Ann Neurol 14:235-241 (Pubitemid 13030278)
77. Piddlesden SJ, Jiang S, Levin JL et al (1996) Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol 71:173-177 (Pubitemid 26413270)
78. Poussin MA, Goluszko E, David CS et al (2001) HLA-DQ6 transgenic mice resistance to experimental autoimmune myasthenia gravis is linked to reduced acetylcholine receptor-specific IFN-gamma, IL-2 and IL-10 production. J Autoimmun 17:175-180 (Pubitemid 33108752)
79. Qi H, Tuzun E, Allman W et al (2008) C5a is not involved in experimental autoimmune myasthenia gravis pathogenesis. J Neuroimmunol 196:101-106
80. Rodgaard A, Nielsen FC, Djurup R et al (1987) Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol 67:82-88 (Pubitemid 17222164)
81. Roncarolo MG, Levings MK, Traversari C (2001) Differentiation of T regulatory cells by immature dendritic cells. J Exp Med 193:F5-F9 (Pubitemid 32524446)
82. Ruff RL, Lennon VA (1998) End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann Neurol 43:370-379 (Pubitemid 28113600)
83. Russel WMS, Burch RL (1959) The principles of humane experimental technique. Special edition published by Universities Federation for Animal Welfare (UFAW), 1992 edn. Methuen & Co., London
84. Sahashi K, Engel AG, Lambert EH et al (1980) Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 39:160-172 (Pubitemid 10141862)
85. Sakaguchi S (2004) Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531-562
86. Sanders DB, Evoli A (2010) Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43:428-435
87. Schönbeck S, Padberg F, Hohlfeld R et al (1992) Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis. J Clin Invest 90:245-250
88. Sheng JR, Li L, Ganesh BB et al (2006) Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells. J Immunol 177:5296-5306 (Pubitemid 44527602)
89. Slater CR, Young C, Wood SJ et al (1997) Utrophin abundance is reduced at neuromuscular junctions of patients with both inherited and acquired acetylcholine receptor deficiencies. Brain 120(Pt 9):1513-1531 (Pubitemid 27389220)
90. Soltys J, Kusner LL, Young A et al (2009) Novel complement inhibitor limits severity of experimentally myasthenia gravis. Ann Neurol 65:67-75
91. Tarrab-Hazdai R, Aharonov A, Silman I et al (1975) Experimental autoimmune myasthenia induced in monkeys by purified acetylcholine receptor. Nature 256:128-130
92. Toro-Goyco E, Cora EM, Kessler MJ et al (1986) Induction of experimental myasthenia gravis in rhesus monkeys: a model for the study of the human disease. PR Health Sci J 5:13-18
93. Toyka KV, Brachman DB, Pestronk A et al (1975) Myasthenia gravis: passive transfer from man to mouse. Science 190:397-399
94. Tzartos S, Hochschwender S, Vasquez P et al (1987) Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol 15:185-194 (Pubitemid 17075151)
95. Tzartos SJ, Kokla A, Walgrave SL et al (1988) Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the alpha subunit. Proc Natl Acad Sci USA 85:2899-2903
96. Ubiali F, Nava S, Nessi V et al (2008) Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. J Immunol 180:2696-2703
97. van der Neut Kolfschoten M, Schuurman J, Losen M et al (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317:1554-1557 (Pubitemid 47417435)
98. Vincent A (1991) Autoimmunity to acetylcholine receptors in myasthenia gravis. Biochem Soc Trans 19:180-183
99. Vincent A (1994) AChR from cell line TE671 cannot replace human muscle AChR in the conventional diagnostic immunoprecipitation RIA. J Neuroimmunol 53:115
100. Vincent A (2002) Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2:797-804
101. Wang ZY, Karachunski PI, Howard JF et al (1999) Myasthenia in SCID mice grafted with myasthenic patient lymphocytes: role of CD4+ and CD8+ cells. Neurology 52:484-497 (Pubitemid 29075592)
102. Wang W, Ostlie NS, Conti-Fine BM et al (2004) The susceptibility to experimental myasthenia gravis of STAT6-/- and STAT4-/- BALB/c mice suggests a pathogenic role of Th1 cells. J Immunol 172:97-103 (Pubitemid 38020460)
103. Wood SJ, Slater CR (2001) Safety factor at the neuromuscular junction. Prog Neurobiol 64:393-429
104. Xiao BG, Duan RS, Link H et al (2003) Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell Immunol 223:63-69 (Pubitemid 36945550)
105. Xiao BG, Duan RS, Zhu WH et al (2006) The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis. Cell Immunol 241:95-101
106. Yang H, Goluszko E, David C et al (2002) Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. J Clin Invest 109:1111-1120 (Pubitemid 34408586)
107. Yang H, Zhang Y, Wu M et al (2010) Suppression of ongoing experimental autoimmune myasthenia gravis by transfer of RelB-silenced bone marrow dentritic cells is associated with a change from a T helper Th17/Th1 to a Th2 and FoxP3+ regulatory T-cell profile. Inflamm Res 59:197-205
108. Yarilin D, Duan R, Huang YM et al (2002) Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis. Clin Exp Immunol 127:214-219 (Pubitemid 34233925)
109. Zhang GX, Xiao BG, Bai XF et al (1999) Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol 162:3775-3781
110. Zhou Y, Gong B, Lin F et al (2007) Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis. J Immunol 179:8562-8567